Teleflex (NYSE:TFX) Price Target Lowered to $120.00 at Truist Financial

Teleflex (NYSE:TFX) had its target price decreased by Truist Financial from $128.00 to $120.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “hold” rating on the medical technology company’s stock. Truist Financial’s price target points to a potential upside of 11.92% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Zacks Research downgraded Teleflex from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 30th. Wells Fargo & Company dropped their target price on shares of Teleflex from $131.00 to $114.00 and set an “equal weight” rating for the company in a research report on Friday. Wall Street Zen cut shares of Teleflex from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 15th. Weiss Ratings reissued a “sell (d+)” rating on shares of Teleflex in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada cut their target price on shares of Teleflex from $135.00 to $120.00 and set a “sector perform” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $134.57.

Teleflex Trading Down 2.0%

TFX stock traded down $2.18 on Monday, hitting $107.22. 211,112 shares of the company were exchanged, compared to its average volume of 741,217. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of 25.24, a price-to-earnings-growth ratio of 1.79 and a beta of 1.05. Teleflex has a twelve month low of $102.58 and a twelve month high of $200.15. The business’s fifty day moving average is $125.66 and its two-hundred day moving average is $123.00.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, November 6th. The medical technology company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.38 by $0.29. The company had revenue of $892.90 million during the quarter, compared to analysts’ expectations of $892.79 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business’s quarterly revenue was up 19.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.49 EPS. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. As a group, research analysts forecast that Teleflex will post 13.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TFX. Pzena Investment Management LLC increased its holdings in Teleflex by 8.8% during the 3rd quarter. Pzena Investment Management LLC now owns 387,483 shares of the medical technology company’s stock worth $47,412,000 after purchasing an additional 31,376 shares during the last quarter. Heartland Advisors Inc. grew its position in shares of Teleflex by 200.0% during the third quarter. Heartland Advisors Inc. now owns 150,000 shares of the medical technology company’s stock worth $18,354,000 after buying an additional 100,000 shares in the last quarter. Rothschild Investment LLC increased its stake in shares of Teleflex by 15,323.5% in the third quarter. Rothschild Investment LLC now owns 2,622 shares of the medical technology company’s stock worth $321,000 after buying an additional 2,605 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Teleflex in the third quarter worth $349,000. Finally, Fifth Third Bancorp raised its holdings in Teleflex by 7.8% in the third quarter. Fifth Third Bancorp now owns 2,083 shares of the medical technology company’s stock valued at $255,000 after acquiring an additional 151 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.